Arca
Skip to content
Tools
Tools

TH: Tyrosine 3-monooxygenase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the conversion of L-tyrosine to L- dihydroxyphenylalanine (L-Dopa), the rate-limiting step in the biosynthesis of catecholamines, dopamine, noradrenaline, and adrenaline.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on TH, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Metyrosine

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        MetyrosineApprovedBausch HealthSmall moleculeInhibitorTyrosine 3-hydroxylase inhibitor1—

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 1 in all, from ClinicalTrials.gov.
        TrialDrugPhaseStatusLead sponsorFirst posted
        SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for SarcomaMetyrosinePhase 2Active, not recruitingSarcoma Oncology Research Center, LLC2018-12-19

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        TH-deficient dopa-responsive dystonia
        0.85
        Dopa-responsive dystonia
        0.64
        Tyrosine hydroxylase deficiency
        0.59
        Dystonia 5
        0.54
        Adrenal gland pheochromocytoma
        0.46
        Intellectual disability
        0.45
        Type 2 diabetes mellitus
        0.44
        Dystonic disorder
        0.43
        Hereditary disease
        0.42
        Hypertensive disorder
        0.38

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1969, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P07101, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.